![Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial | Journal of Clinical ... Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial | Journal of Clinical ...](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2022/jco.2022.40.issue-18/jco.21.02051/20220607/images/large/jco.21.02051t2.jpeg)
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial | Journal of Clinical ...
![Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine–cisplatin and high dose-intensity MVAC | SpringerLink Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine–cisplatin and high dose-intensity MVAC | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00432-021-03582-x/MediaObjects/432_2021_3582_Fig1_HTML.png)
Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine–cisplatin and high dose-intensity MVAC | SpringerLink
![Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial | Journal of Clinical ... Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial | Journal of Clinical ...](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2022/jco.2022.40.issue-18/jco.21.02051/20220607/images/large/jco.21.02051t1.jpeg)
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial | Journal of Clinical ...
![A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer - Clinical and Translational Radiation Oncology A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer - Clinical and Translational Radiation Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/bf432703-29f0-409e-83e2-5c0786403874/gr1_lrg.jpg)
A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer - Clinical and Translational Radiation Oncology
![Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial ... Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial ...](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/eb32f9e5-3cab-45be-9d54-7dd1fd7d2bb5/gr1_lrg.jpg)
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial ...
![Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03) - ScienceDirect Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419371972-gr2.jpg)
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03) - ScienceDirect
![Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial) | BMC Cancer | Full Text Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial) | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-021-08990-3/MediaObjects/12885_2021_8990_Fig1_HTML.png)
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial) | BMC Cancer | Full Text
![1438-Bladder/Urothelial neoadjuvant MVAC (methotrexate vinBLASTine DOXOrubicin ciSplatin) SUPERSEDED | eviQ 1438-Bladder/Urothelial neoadjuvant MVAC (methotrexate vinBLASTine DOXOrubicin ciSplatin) SUPERSEDED | eviQ](https://www.eviq.org.au/getmedia/00c74062-b76d-4321-a9ca-0c630e730033/1438-NEJM-2003-Grossman-toxicity.png.aspx)
1438-Bladder/Urothelial neoadjuvant MVAC (methotrexate vinBLASTine DOXOrubicin ciSplatin) SUPERSEDED | eviQ
Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience | PLOS ONE
Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cys
Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience | PLOS ONE
Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience | PLOS ONE
![Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03) - Annals Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03) - Annals](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/914ef13c-f9ce-4971-82bb-d3c07163b60c/gr1.jpg)
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03) - Annals
![Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial | Journal of Clinical ... Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial | Journal of Clinical ...](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2022/jco.2022.40.issue-18/jco.21.02051/20220607/images/medium/jco.21.02051t3.gif)
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial | Journal of Clinical ...
![Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial - European Urology Oncology Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial - European Urology Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/be243ab5-73b7-470c-a2e5-17f48dfdf1f8/gr1.jpg)